US Edition4 Articles
4 Articles
All
Left
1
Center
1
Right
Harrow Acquires US Commercial Rights to Byqlovi for Postoperative Inflammation and Pain
Harrow and Taiwan-based Formosa Pharmaceuticals announced a licensing agreement in which Harrow has acquired the exclusive US commercial rights for Byqlovi (clobetasol propionate ophthalmic suspension) 0.05%. Financial terms of the deal were not disclosed. Byqlovi was approved by the FDA in March 2024 for the treatment of postoperative inflammation and pain following ocular surgery and is the first new ophthalmic steroid in its class in over 15…
Coverage Details
Total News Sources4
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
